Skip to main content

Table 3 Associations between Illness perceptions and allopurinol use

From: Illness perceptions of gout patients and the use of allopurinol in primary care: baseline findings from a prospective cohort study

 

Using allopurinol

 

Adjusted relative risk ratio (RRR) (95 % CI)

Yes (%)

No (%)

Unadjusted RRR (95 % CI)

Age, gender, deprivation, BMI, alcohol & co-morbidities

Age, gender, deprivation, BMI, alcohol, co-morbidities & gout characteristics

A lot I can do to control my gout

 Disagree (N = 154)

78 (12.7)

76 (16.2)

REF

REF

REF

 Uncertain (N = 375)

190 (30.8)

185 (39.5)

1.00 (0.69 to 1.46)

1.01 (0.67 to 1.51)

1.10 (0.70 to 1.73)

 Agree (N = 555)

348 (56.5)

207 (44.3)

1.64 (1.14 to 2.34)

1.66 (1.12 to 2.45)

1.39 (0.89 to 2.17)

 Nagelkerke r2, Pearson GOF

   

0.094, p= 0.053

0.18, p = 0.43

What I do will affect my gout

 Disagree (N = 104)

64 (10.5)

40 (8.5)

REF

REF

REF

 Uncertain (N = 487)

264 (43.3)

233 (49.4)

0.74 (0.48 to 1.14)

0.66 (0.41 to 1.04)

0.74 (0.44 to 1.23)

 Agree (N = 480)

281 (46.2)

199 (42.1)

0.88 (0.57 to 1.36)

0.82 (0.51 to 1.31)

0.69 (0.41 to 1.16)

 Nagelkerke r2, Pearson GOF

   

0.07, p = 0.65

0.12, p = 0.91

Treatments are effective

 Disagree (N = 75)

32 (5.2)

43 (9.3)

REF

REF

REF

 Uncertain (N = 180)

73 (11.8)

107 (23.1)

0.92 (0.53 to 1.58)

0.98 (0.54 to 1.79)

1.06 (0.54 to 2.06)

 Agree (N = 827)

513 (83.0)

314 (67.6)

2.20 (1.36 to 3.54)

2.24 (1.32 to 3.81)

1.78 (0.96 to 3.29)

 Nagelkerke r2, Pearson GOF

   

0.12, p= 0.11

0.29, p = 0.54

Gout is serious

 Disagree (N = 63)

33 (5.3)

30 (6.4)

REF

REF

REF

 Uncertain (N = 195)

98 (15.8)

97 (20.6)

0.92 (0.52 to 1.62)

0.79 (0.42 to 1.50)

0.91 (0.43 to 1.89)

 Agree (N = 834)

490 (78.9)

344 (73.0)

1.29 (0.78 to 2.16)

1.15 (0.65 to 2.05)

1.15 (0.59 to 2.26)

 Nagelkerke r2, Pearson GOF

   

0.09, p = 0.39

0.12, p = 0.96

  1. Bold: p = <0.05. GOF goodness-of-fit